Navigation Links
ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
Date:9/12/2007

in their own country, who speaks their own dialect, and understands their own customs and religious variations."

The ReBuilder System(R) is an electronic device that restores nerve function, increases blood flow, cancels pain, and reduces numbness and tingling that sells for $399-$699 retail and is available via the Internet.

Twenty million, eight hundred thousand children and adults, or 7% of the U.S. population suffer from diabetes. Thirty percent of those diagnosed with diabetes will eventually suffer from peripheral neuropathy, pain and numbness in the feet and hands that can lead to complete loss of mobility, gangrene, and eventual amputations. $132 Billion per year is the current cost of treating diabetes, or 1 of every 10 health care dollars spent. Neuropathy sufferers constitute 33% of this market, or 43.56 billion dollars in potential market. ReBuilder Medical Technologies, Inc. is a company in its infancy that has targeted 1% of this market, or $43.5 million dollars in its next two market years, and is on course to meet this goal. Its only primary competition is from drug companies whose therapy has proven less successful and prone to side-effects and addiction.

About ReBuilder Medical Technologies, Inc.:

ReBuilder Medical Technologies, Inc is an emerging medical device manufacturer of innovative technologies founded by world renowned medical device inventor David B. Phillips, Ph.D. ReBuilder Medical Technologies's flagship product is its FDA registered ReBuilder System(R) for treating peripheral neuropathy. Unlike current therapies for neuropathy (nerve disease) which focus on prescription drugs with powerful side effects, the ReBuilder System(R) is a portable, battery powered medical product that provides a new non-surgical treatment which is non-invasive, has no side effects and can actually strengthen muscles while increasing blood flow.

ReBuilder Medical also manufactures the Phillips Molluscum Treatment System(TM) for t
'/>"/>

SOURCE ReBuilder Medical Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Check if your “Favourite medical web-site” is indulging in Quackey
2. Teens turning to Internet for medical queries
3. Robots craft medical history
4. NBE to conduct test for medical students from abroad
5. Air pollution combined with greater medical needs
6. Indian Nationals with Foreign Medical Degrees can now practice in India
7. Children! Protecting them from medical mistakes
8. More information sought by patients on medical errors
9. SARS necessitates medical masks
10. Meditation Works Medically
11. Sleep Disorders Could Indicate Other Medical Problems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... 17, 2014U.S. military personnel who served in Iraq ... traumatic brain injury (TBI) were compared to military ... medical reasons. Differences in measures of overall disability, ... after injury are reported in an article in ... from Mary Ann Liebert, Inc., publishers. The article ...
(Date:4/17/2014)... a new mechanism that allows blood to enter the ... and the Salk Institute have opened the door to ... damage. , A complex and devastating neurological condition, stroke ... for disability in the U.S. The blood-brain barrier is ... into the brain, causing the permanent deficits in movement ...
(Date:4/17/2014)... international research team led by Cesar A. Arias, M.D., ... at Houston (UTHealth) has identified a new superbug that ... report appeared in the April 17 issue of ... new superbug is part of a class of highly-resistant ... MRSA, which is a major cause of hospital and ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:New MRSA superbug emerges in Brazil 2
... at the Swedish medical university Karolinska Institutet have discovered ... inflammatory substances in their brains. Their findings offer hope ... affect the immune system. The causes of ... of effective treatments. One theory is that infections caught ...
... stimulates collagen production in fibroblasts and hepatic stellate ... the development of liver fibrosis. Hepatoprotective effects of ... induced liver fibrosis were reported in many studies. ... dimethylnitrosamine (DMN)-induced models has not been studied. ...
... or stall carotid artery disease , WEDNESDAY, Nov. 18 ... no additional benefit to seniors with coronary artery disease ... say. , The 18-month study of 145 Baltimore-area men ... in arterial wall thickness reductions between those who took ...
... quickly is critical, experts say , WEDNESDAY, Nov. 18 ... and communities in new guidelines for treatment of coronary ... should have an organized system of emergency care for ... they get to hospitals and strategies for getting ...
... , ... of the StreetSmarts® sales knowledge sharing platform and ELA’s sales expertise offers a winning ... ... Inc., developer of the on-demand sales effectiveness , knowledge and collaboration ...
... , LONDON, Nov. 18 XL Insurance, the global insurance ... today announced the strengthening of its equine capabilities with the ... Underwriting Limited ("Unicorn"), a subsidiary of THB Group plc. ... who has over 20 years of underwriting experience in the ...
Cached Medicine News:Health News:Immune system activated in schizophrenia 2Health News:Niacin Adds No Benefit for Statin Patients: Study 2Health News:New Heart Attack Treatment Guidelines Stress Coordination 2Health News:New Heart Attack Treatment Guidelines Stress Coordination 3Health News:StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 2Health News:StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 3Health News:StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 4Health News:XL Insurance Strengthens Equine Underwriting Team 2
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... developing its Symphony® CGM System as a non-invasive, wireless ... F. Doman , Executive Chairman and Interim CEO of ... Markets, Tenth Annual Equity Conference. Mr. ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Sept. 3 Forest Laboratories, Inc.,(NYSE: ... announced results from,two global Phase III studies ... for the treatment of patients with chronic,obstructive ... I&II,(AClidinium CLinical Trial Assessing Efficacy and Safety ...
... Efficacy ... Endpoints, Company to Host Conference Call and Webcast Wednesday, September ... 8:30 am ET ... NBIX ) today announced positive safety and efficacy results,from its third Phase II clinical ...
Cached Medicine Technology:Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 2Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 3Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 4Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 5Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 6
A convenient, rotating standholds up to seven Gilson pipettes (any model) with exceptional stability. Protects your precious pipettes from possible damage or contamination....
Inquire...
... solution for scheduling, performing and documenting ... pipettes and liquid handling devices. Collects ... Supports all gravimetric calibration protocols ... NCCLS and GLP requirements Includes ...
... V-shaped bottom allows easy withdrawal of solution ... bag ,• Corner pouring lips facilitate ... designed for 4, 8, and 12 channel ... withdrawal of practically all of the solution. ...
Medicine Products: